Advarra, Inc.

Based in the US, Advarra, Inc. is a company that specializes in providing comprehensive services to enhance the effectiveness of clinical trials, including IRB services and innovative technology solutions. Advarra, Inc. was founded in 2017 in Columbia, US, focusing on clinical research services.

The company has completed 2 deals, with the most recent deal being in June 2021. Gadi Saarony is the CEO, and the founder is MAS Shakil Khan. In June 2022, Blackstone Group and CPP Investment Board acquired a majority stake in Advarra from Genstar Capital Partners and Linden, completing the deal in August 2022. Advarra offers a range of services aimed at improving clinical trial efficiency.

Their core services include institutional review board (IRB) services, institutional biosafety committee (IBC) reviews, and a technology platform that integrates data and communication. Their technology solutions, such as the eRegulatory Management System and Advarra Insights, assist in enhancing regulatory efficiency and data analytics. The company serves over 3,500 institutions, including hospitals and academic medical centers, with a strong presence in North America and Europe, particularly in oncology and gene therapy. In the most recent year reported, Advarra achieved an EBITDA of USD 72.

20 mn, primarily derived from its IRB and IBC services and technology solutions offered to clients including sponsors and research institutions. Following the acquisition completed in August 2022, Advarra aims to leverage the support from Blackstone Group and CPP Investment Board to enhance its clinical research capabilities. Plans are underway to develop new products and expand its market presence, focusing on making clinical research smarter, safer, and faster. Specific details on new products and geographic expansions are expected to be outlined in upcoming announcements.